Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204025 | 0.94 | KMT2A (0.54) | KDM4EKMT2ANPC1GPR183MAPT | |
| SCHEMBL521554 | 0.85 | KMT2A (0.48) | KDM4EKMT2ANPC1GPR183MAPT | |
| SCHEMBL2205649 | 0.85 | IGF1R (0.46) | KMT2ASMN1; SMN2LMNA | |
| SCHEMBL2206362 | 0.82 | IGF1R (0.48) | KMT2ASMN1; SMN2LMNA | |
| SCHEMBL2204698 | 0.82 | KMT2A (0.53) | KDM4EKMT2ANPC1GPR183MAPT | |
| SCHEMBL3108425 | 0.82 | KMT2A (0.45) | KDM4EKMT2ANPC1GPR183MAPT | |
| SCHEMBL2062110 | 0.80 | RAB9A (0.45) | KDM4EKMT2ANPC1MAPTALDH1A1 | |
| SCHEMBL2061703 | 0.78 | ALDH1A1 (0.48) | KDM4EKMT2ANPC1ALDH1A1ABCB1 | |
| SCHEMBL2061343 | 0.78 | L3MBTL1 (0.49) | KDM4EKMT2ANPC1MAPTDPP8 | |
| SCHEMBL2206864 | 0.78 | IGF1R (0.49) | KMT2AALDH1A1MEN1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1920067-B1 | ENZYME DETECTION TECHNIQUE | KIMBERLY CLARK CO (US) | 2015-06-03 | — | — | EP | claimed |
| EP-1920067-A2 | ENZYME DETECTION TECHNIQUE | Kimberly-Clark Worldwide, Inc. (US) | 2008-05-14 | — | — | EP | claimed |
| WO-2007027234-A2 | ENZYME DETECTION TECHNIQUE | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-03-08 | — | — | WO | claimed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2010131127-A2 | ABSORBENT ARTICLES CAPABLE OF INDICATING THE PRESENCE OF URINARY TRACT INFECTIONS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2008075217-A2 | LATERAL FLOW ASSAY DEVICE AND ABSORBENT ARTICLE CONTAINING SAME | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1920067-A2 | ENZYME DETECTION TECHNIQUE | Kimberly-Clark Worldwide, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1920253-A2 | DETECTION OF PROTEASES SECRETED FROM PATHOGENIC MICROORGANISMS | Kimberly-Clark Worldwide, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1920251-A1 | NITRITE DETECTION TECHNIQUE | Kimberly-Clark Worldwide, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008053390-A1 | ABSORBENT ARTICLE CONTAINING LATERAL FLOW ASSAY DEVICE | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007027198-A1 | NITRITE DETECTION TECHNIQUE | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027234-A2 | ENZYME DETECTION TECHNIQUE | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027353-A2 | DETECTION OF PROTEASES SECRETED FROM PATHOGENIC MICROORGANISMS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | KDM4E 729/4885KMT2A 501/4885NPC1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.